drugset / Trial / NCT00031980

Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer

NCT00031980

NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer.

Timeline

Start
2002-03
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide Oral